Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes.
about
Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequencesA clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersIntegrative meta-analysis of differential gene expression in acute myeloid leukemiaEpigenetic changes in the myelodysplastic syndrome.Epigenetic therapies in MDS and AMLDecitabine in the treatment of myelodysplastic syndromes.Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patientsGemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.Similarities and differences between therapy-related and elderly acute myeloid leukemia.Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia.The silence of the genes: epigenetic disturbances in haematopoietic malignancies.Quantitative analyses of DAPK1 methylation in AML and MDSThe genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights.Quantitative Detection of ID4 Gene Aberrant Methylation in the Differentiation of Myelodysplastic Syndrome from Aplastic AnemiaReduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemiaERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.Epigenetics in acute myeloid leukemia.Models of granulocyte DNA structure are highly predictive of myelodysplastic syndromeDNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights.Evaluating DAPK as a therapeutic target.tp53-dependent G2 arrest mediator candidate gene, Reprimo, is down-regulated by promoter hypermethylation in pediatric acute myeloid leukemia.Clinicopathological significance and potential drug target of p15INK4B in multiple myeloma.Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies.Clinical implications of SOCS1 methylation in myelodysplastic syndrome.Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients.Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome.Discovery of Novel and Selective DNA Methyltransferase 1 Inhibitors by Pharmacophore and Docking-Based Virtual Screening
P2860
Q24813458-56E3E9FE-7128-40E8-BBB1-A25A820B1AF7Q26743743-1075B1C9-E3AE-4B7F-8016-09DFB22D29A2Q33538043-4F046895-E764-4E85-9453-AB597D20B6D3Q33767309-FE483EA9-F5C1-4D33-BE2D-3B51726F63E7Q33863567-3131FFDC-FF85-45A6-901A-3EF04ACCA0C7Q34088403-CFFB1699-F134-4F6F-BEDC-EC77F6E7324FQ34426853-B33ED80E-77CC-48B7-9BCF-AD5C2D174C38Q34557714-8B9AE6C9-41EB-4591-9D98-B6BB5B5277DBQ35640731-360109B4-91DF-482F-B9AF-693DD04935B0Q35882742-8B28B54C-44C8-4DC1-A4C4-2CCCB9F1BAE1Q36066276-AECFADAF-CD0F-4035-AA03-300B8F1A9E32Q36296317-F6B22639-71D1-4C91-97B4-E49A47345E0AQ36415991-EFEABFA9-A778-4B83-AF88-325D2E50418CQ36477232-D14051F9-2BFC-434C-9B26-8BAD56FAE925Q36612343-5EA0056A-8B18-4031-B517-AFE3816BBB5FQ37190494-56FDFD44-92B9-4365-9B61-08C4CB0D4BACQ37240566-32354825-15CB-48E5-AFD3-79896FC0E1E7Q37415850-EF0F51E8-7F21-482B-876B-0C62EDDC7216Q37797467-18BB875D-85A4-4134-9203-81A275E19ED4Q38168688-900AC4BF-6F58-40A8-857B-76E95BD9E562Q38915689-520BD049-E763-4EC6-94E0-84343A6AEE18Q41816008-2881D2C7-90FE-4DBB-B631-4AFA7D413ADBQ42814347-74145843-4866-4AA8-9D11-9DB3E8A9D20FQ47340953-849AA2AE-29C8-4A34-BEC1-3C11689C33F6Q54580979-5F026620-2B12-4364-A77B-5D51882DF3A4Q54642861-F5533E1C-5A01-42FD-8CF0-C6F8CFB025A1Q54652930-561D8D1F-D821-4101-92DB-F2B360007D40Q57267577-DEB470EC-6284-46AD-8611-458941383EAC
P2860
Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Aberrant methylation of DAP-ki ...... and myelodysplastic syndromes.
@ast
Aberrant methylation of DAP-ki ...... and myelodysplastic syndromes.
@en
Aberrant methylation of DAP-ki ...... and myelodysplastic syndromes.
@nl
type
label
Aberrant methylation of DAP-ki ...... and myelodysplastic syndromes.
@ast
Aberrant methylation of DAP-ki ...... and myelodysplastic syndromes.
@en
Aberrant methylation of DAP-ki ...... and myelodysplastic syndromes.
@nl
prefLabel
Aberrant methylation of DAP-ki ...... and myelodysplastic syndromes.
@ast
Aberrant methylation of DAP-ki ...... and myelodysplastic syndromes.
@en
Aberrant methylation of DAP-ki ...... and myelodysplastic syndromes.
@nl
P2093
P1433
P1476
Aberrant methylation of DAP-ki ...... and myelodysplastic syndromes.
@en
P2093
Alessandra Scardocci
Antonella Di Mario
Francesco Guidi
Giuseppe Leone
Livio Pagano
Maria Teresa Voso
Stefan Hohaus
P304
P356
10.1182/BLOOD-2003-07-2249
P407
P577
2003-09-22T00:00:00Z